Journal profile · Pharmacology & Pharmacy
Annals of Pharmacotherapy
ISSN 1060-0280 · eISSN 1542-6270 · SAGE Publications Inc. · UNITED STATES · Monthly · Founded 1992
Annals of Pharmacotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.46; hybrid open access; APC about USD 4,400; review about 51 days (submission to acceptance, publisher); community-reported acceptance: easy; 164 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Annals of Pharmacotherapy is published by SAGE Publications Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmaceutical Practices and Patient Outcomes, Pharmaceutical studies and practices and Antibiotics Pharmacokinetics and Efficacy, together about 29.6% of its articles. Its main subfields are Pharmacology. (generated from OpenAlex topic counts and CAS ranking data)
Annals of Pharmacotherapy is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE).Research articles may report well-designed studies of medication effectiveness, adverse events, interactions, adherence, pharmacoeconomics, pharmacokinetics, pharmacogenomics, pharmacoepidemiology, informatics and use to positively impact patient care.Review articles may describe evidence-based comprehensive, critical and analytical assessments of specific important or controversial subjects. These would include reviews of new drugs, drug classes, therapeutic controversies, and the state-of-the-art strategies to enhance the treatment and prevention of diseases.Commentaries and Editorials may offer perspectives on diverse therapeutic or professional issues influencing health care, medicine and pharmacy.Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the AOP editorial office at AOP@sagepub.com.Submit your manuscript today at https://mc.manuscriptcentral.com/aop.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Milap C. NahataPublisher website
Editorial board by country: none in mainland China; most named United States 78, Canada 10, Australia 2, Hong Kong, China 1, Spain 1 (95 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmaceutical Practices and Patient OutcomesMedicine13.4%
- Pharmaceutical studies and practicesMedicine9.5%
- Antibiotics Pharmacokinetics and EfficacyMedicine6.7%
- Pharmacological Effects and Toxicity StudiesMedicine5%
- Medication Adherence and ComplianceMedicine4.5%
- Atrial Fibrillation Management and OutcomesMedicine4.1%
- Drug-Induced Adverse ReactionsMedicine4.1%
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.46LetPub ·
- Impact factor (publisher)
- 2.5Publisher website ·
- 5-year impact factor (publisher)
- 2.7Publisher website ·
- CiteScore 2026-06
- 5.8LetPub ·
- SJR 2026-06
- 0.82LetPub ·
- SNIP 2026-06
- 1.09LetPub ·
- h-index
- 102LetPub ·
- h-index
- 155OpenAlex ·
- i10-index
- 6,331OpenAlex ·
- 2-year mean citedness
- 1.76OpenAlex ·
- Self-citation rate
- 4%LetPub ·
- Share of gold OA articles
- 5.83%LetPub ·
Volume
- Articles per year
- 120LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 16,778 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 120 | 27 | 19 |
| 2025 | 164 | 50 | 208 |
| 2024 | 121 | 39 | 487 |
| 2023 | 153 | 62 | 1,095 |
| 2022 | 181 | 25 | 1,635 |
| 2021 | 173 | 24 | 1,897 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
51 dayssubmission to acceptance · community reports 3–8 weeks
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 24%Publisher website ·
- Submission to first decision
- 14 daysPublisher website ·
- Submission to acceptance
- 51 daysPublisher website ·
- Acceptance to publication
- 42 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,400 / GBP 3,226 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Submission fee
- USD 800
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Abstract
- ≤ 250 words
- Reference style
- AMA
Article types accepted8
- meta-analysisRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
- original researchRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
- research reportRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
- research reportsRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
- reviewRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
- review articleRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
- review articlesREVIEW ARTICLES: Comprehensive, significant, critical, and analytical reviews that include essential information on a well-delineated subject.Length not stated
- systematic reviewRESEARCH REPORTS: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence a…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Author contributions
You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage. Criteria for Authorship All authors must have fulfilled the criteria for autho…
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Member of Committee on Publication Ethics (COPE) Model summary
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
There are no fees payable to submit or publish in this journal. Figures submitted in color will be published in color in the online version of the journal at no cost. If you wish to have color figures in the printed version, the following fees apply: To print figures in color there is a cost to the authors of $800 for the first page and $200 for each additional page. Optional open access publishin…
Source ↗Publisher website ·- Peer review Peer review policy
Double anonymized peer review Model summary
The following summary describes the peer review process for this journal: Identity transparency: Double Anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
Accepts preprint submissions Model summary
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE Publications Inc.
- Country or region
- UNITED STATES
- Language
- Multi-Language
- Frequency
- Monthly
- Founded
- 1992
- ISSN
- 1060-0280
- Electronic ISSN
- 1542-6270
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Annals of Pharmacotherapy
What CAS zone is Annals of Pharmacotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Annals of Pharmacotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Annals of Pharmacotherapy?
The latest impact factor listed by LetPub is 2.46; CiteScore 5.8, h-index 155.
How long does peer review take at Annals of Pharmacotherapy?
The publisher reports about 51 days (submission to acceptance); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 24%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Annals of Pharmacotherapy?
According to the journal's author guidelines: Abstract: ≤ 250 words; Reference style: AMA. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Annals of Pharmacotherapy based?
Of the 95 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (78), Canada (10) and Australia (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Annals of Pharmacotherapy?
According to LetPub and DOAJ records, Annals of Pharmacotherapy is indexed in SCIE and Scopus.
Is Annals of Pharmacotherapy open access, and what is the APC?
Annals of Pharmacotherapy is a hybrid journal. For open-access publication: APC about USD 4,400.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .